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S u m m a r y  
Becker muscular dystrophy is an X-linked disease due to mutations of  the dystrophin gene. We 
now show that neuronal-type nitric oxide synthase (nNOS), an identified enzyme in the dys- 
trophin complex, is uniquely absent from skeletal muscle plasma membrane in many human 
Becker patients and in mouse models of dystrophinopathy. An NH2-terminal domain of 
nNOS directly interacts with cxl-syntrophin but not with other proteins in the dystrophin 
complex analyzed. However, nNOS does not associate with cll-syntrophin on the sarcolemma 
in transgenic mdx mice expressing truncated dystrophin proteins. This suggests a ternary inter- 
action of nNOS, ~l-syntrophin, and the central domain of dystrophin in vivo, a conclusion 
supported by developmental studies in muscle. These data indicate that proper assembly of  the 
dystrophin complex is dependent upon the structure of  the central rodlike domain and have 
implications for the design ofdystrophin-containing vectors for gene therapy. 
M utations of  the X-linked dystrophin gene are the most common cause of  inherited muscular dystro- 
phy and affect ~1:3,500 male births (1). Duchenne muscu- 
lar dystrophy (DMD) I, the more common and more severe 
form of  the disease, is associated with mutations that lead to 
an absence of  dystrophin protein in muscle (2, 3). A clini- 
cally milder disease, Becket muscular dystrophy (BMD), 
accounts for ~20% of cases and often involves deletions 
within the rodlike central domain of  dystrophin (4). Mus- 
cle dystrophin levels are often nearly normal in BMD, 
which can preclude diagnosis by immunohistochemical 
analysis ofdystrophin (5). 
Dystrophin is a large intracellular protein containing sev- 
eral defined sequence motis (6). An NH2-terrninal cx-acti- 
nin-like domain binds to F-actin (7), and is followed by a 
large rod domain that shares sequence homology with the 
structural repeats in spectrin. The C O O H  terminus is 
unique to dystrophin and related proteins, and this region 
~ Abbreviations used in this paper: oe-BGT, alpha bungaro-toxin; AChR, ace- 
tylcholine receptor; BMD, Becket muscular dystrophy; DMD, Duchenne 
muscular dystrophy; GST, glutathione-S-transferase; nNOS, neural-type 
nitric oxide synthase; NO, nitric oxide; PH, pleckstrim homology. 
direcdy binds to a glycoprotein complex in skeletal muscle 
(8-10). The structural dystrophin-associated complex in- 
cludes intracellular proteins, syntrophins (11), as well as in- 
tegral membranes proteins, the dystroglycans (12) and 
sarcoglycans; the absence of  dystrophin in DMD causes a 
disruption of this complex (13). These interactions suggest 
a structural role for dystrophin, physically linking the extra- 
cellular matrix to the muscle cytoskeleton (14). In support 
of this model, genetic mutations in components of  the 
sarcoglycan complex can cause autosomal recessive muscu- 
lar dystrophy (15-18). 
Restoration of a functional dystrophin molecule to mus- 
cle represents a primary goal for therapy. To better under- 
stand mechanisms for assembly of  the dystrophin complex 
and to identify potential constructs for gene therapy, frag- 
ments of  dystrophin have been targeted to skeletal muscle 
of transgenic mdx mice, which lack endogenous dystro- 
phin. Replacement with either a full-length dystrophin, a 
COOH-terminal construct encoding 71 kD of  dystrophin, 
Dp71, or a dystrophin minigene, lacking a large portion of  
the central spectrinlike repeats, restores the structural dys- 
trophin complex to muscle. P..eplacement with full-length 
dystrophin corrects muscular dystrophy in mdx mice (19). 
Despite apparent restoration of the dystrophin complex, 
mdx mice targeted with Dp71, still display severe muscular 
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dystrophy (8, 9), whereas those containing the minigene, 
have a very. mild disease phenotype (20, 21). These results 
indicate that all components o f  the dystrophin membrane 
cytoskeleton are needed to completely prevent symptoms 
o f  muscular dystrophy. 
In addition to their cytoskeletal role, dystrophin and as- 
sociated proteins have been implicated in specific signaling 
functions o f  the junctional and extrajunctional sarcolemma. 
The dystrophin-related protein, utrophin, is concentrated 
at neuromuscular endplates and is implicated in acetylcho- 
line receptor (AChl<) clustering, ot-dystroglycan binds with 
high affinity to agrin and laminin suggesting that the dys- 
trophin-associated complex may serve as a link between 
the extracellular matrix and intracellular events that help 
form AChR. clusters (22, 23). Signaling by the dystrophin 
complex may be mediated in part by nitric oxide (NO), a 
messenger molecule in muscle that can regulate myocyte 
development (24), AChR. function (25), and muscle con- 
tractility (26). N O  is formed in skeletal muscle by the neu- 
ronal-type nitric oxide synthase (nNOS) that is enriched at 
the sarcolemma of  fast twitch muscle fibers in rodents (26) 
and in both fast and slow twitch fibers in primates (27). 
R.ecent studies identify n N O S  as a nonstructural compo-  
nent o f  the dystrophin complex (28). Furthermore, n N O S  
is absent from skeletal muscle sarcolemma of  mdx mice and 
in D M D  (28). Biochemical studies in vitro demonstrate 
that the N H  2 terminus o f  nNOS,  which contains a PDZ 
protein motif, directly binds to a similar moti f  in cel-syn- 
trophin (29); furthermore, n N O S  and od-syntrophin 
coimmunoprecipitate from muscle extracts. Direct binding 
of  n N O S  to dystrophin or other associated proteins has not 
yet been demonstrated. 
D M D  and mdx mice show primary dystrophin defi- 
ciency and secondary deficiencies o f  sarcoglycans, dystro- 
glycans, syntrophins, and nNOS.  BMD in humans, due to 
abnormal dystrophin, generally retains dystrophin-associated 
proteins, though n N O S  has not been evaluated. We now 
show that n N O S  is properly restored to the plasma mem-  
brane in transgenic mdx mice expressing full-length human 
dystrophin but is selectively absent from skeletal muscle 
membranes in mdx mice expressing either Dp 71 (DMD 
phenotype) or a dystrophin minigene lacking many of  the 
spectrinlike repeats (very mild BMD phenotype). Dyslocal- 
ization o f  n N O S  in the transgenic mouse nmdels is associ- 
ated with disruption o f  the normal nNOSAxl-syntrophin  
interaction. In human biopsies, we note that loss of  sar- 
colemmal n N O S  is commonly observed in BMD. In some 
patients, lacking as little as three exons in the spectrinlike 
domain of  dystrophin, the absence of  sarcolemmal nNOS 
represents the only identified immunohistochemical abnor- 
mality. 
Materials and Methods  
Antibodies. The following primary antibodies were used: 
nNOS polyclonal raised against homogenous nNOS protein pu- 
rified from rat cerebellum (30), nNOS monoclonai (Transduction 
Labs, Lexington, KY), od-syntrophin polyclonal, syntrophin 
monoclonal (31), dystrophin monoclonal (Signna Chemical Co., 
St. Louis, MO), [3-dystroglycan monoclonal, utrophin mono- 
clonal, and a-sarcoglycan rnonoclonal (Novacastra Laboratories 
Ltd., Newcastle upon Tyne, UK). 
lmmunofluorescence. Unfixed skeletal muscle samples were 
flash frozen in liquid nitrogen-cooled isopentane, sectioned on a 
cryostat (10 Ixm), and melted directly onto glass slides. Sections 
were then postfixed in 2% paraformaldehyde in PBS or cold ace- 
tone. Tissues were "blocked" in PBS containing 1% normal goat 
sermn. Primary antibodies were diluted in blocking reagent and 
were applied to sections overnight at 4~ For indirect immuno- 
fluorescence, secondary goat anti-rabbit FITC-, or donkey anti- 
mouse Cy-3-conjugated antibodies were used according to the 
manufacturer's specifications (The Jackson Laboratory, Bar Har- 
bor, ME; 1:200)_ Cy-3-conjugated 0~-BGT (kindly provided by 
Peter Sargent, University of California, San Francisco) was di- 
luted together with the secondary antibody t-or double labeling 
motor endplates. 
Tissue Extraction1 and Western Blot Analysis. Mouse quadriceps 
skeletal nmscle was homogenized in 1(1 volumes (wt/vol) of 
buffer A (25 mM Tris-HC1, pH 7.4, 100 mM NaCl, 1 mM 
EDTA, l mM EGTA, and 1 mM PMSF), and heavy, microsomes 
were prepared by a standard protocol with minor modifications. 
Nuclei were pelleted by centrifugation at 1,000 ,~. The superna- 
tant was then centrifuged at 20,000 ,~, yielding supernatant S~. 
The resulting heavy microsomal pellet was resuspended in buffer 
A containing 500 mM NaC1, incubated for 30 rain at 4~ with 
agitation, and centrifuged at 15,000 ,~, yielding supernatant S,. 
This resulting pellet was resuspended in buffer A containing 5~0 
mM NaC1 plus 0.5% Triton X-100, incubated for 30 mm at 4o( ", 
with agitation, and centrifuged at 15,000 ,~, yielding supernatant 
$3 and a final pellet P. 
Tissue extracts were resolved by SDS-PAGE (7.5% acryla- 
mide) and proteins were transferred to polyvinylidene fluoride 
membranes (hnmobilon-P; Millipore Corp., Bedford, MA). 
Membranes were incubated overnight with primary antisera diluted 
in Tris-HC1 buffered saline containing 1% BSA, hnnmnoreactive 
bands were visualized by the enhanced chemiluminescence sys- 
tem according to the manufacturer's specifications (Amersham 
Corp., Arlington Heights, ILl. 
Immunoprecipitation. Polyctonal antibodies (1 ~g) to od-syn- 
trophin or noninmmne serum were added to 0.5-ml aliquots of 
solubilized skeletal muscle membranes from wild-type mouse 
(1 mg/ml) or total solubilized nmscle extract from mdx mouse 
(2 mg/ml), and samples were incubated on ice fbr 1 h. Protein 
A-Sepharose (50 p,1) was used to precipitate antibodies. Protein A 
pellets were washed three times with buffer containing I{t0 mM 
NaCI and 1% Triton X-100. Immunoprecipitated proteins were 
denatured with loading buffer and resolved by SDS-PAGE. 
Fusion P~vtein Aflb~ity Chromatq~raphl,. A thsion protein of 
glutathione-S-transferase (GST) fused to the first 299 amino acids 
of nNOS was expressed in Escheridzia coil and purified on glu- 
tathione Sepharose beads as described (28). Solubilized skeletal 
muscle membranes were incubated with control ((;ST) or GST- 
nNOS (1-299) beads. Samples were loaded into disposable col- 
unms washed with 5(1 volumes of buffer containing 0.5% Triton 
X-I(10 plus 3(}(I mM NaC1, and proteins were eluted with 150 p,1 
of SDS-PAGE loading buffer. 
Characterization qfHumal~ Tissues. All human muscle biopsies 
were obtained for diagnostic purposes (dystrophin analysis), and 
were flash frozen in isopentane cooled in liquid nitrogen. Patients 
were evaluated for dystrophin expression by immunofluorescence 
and Western blotting as described (32, 33). Mutation detection in 
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BMD patients was done by multiplex PCR, as previously de- 
scribed. Mutation detection in or (adhalin) was done 
by R T - P C R  and single strand conformation polymorphism, with 
aberrant conformers sequenced as previously described (34); one 
patient was homozygous for an Arg77Cys mutation whereas an- 
other was a compound heterozygote, Leu31Pro and Arg284Cys. 
All biopsies used in this study were deemed to be of excellent 
preservation based on hematoxylin and eosin staining of cryosec- 
tions. 
Results  
Previous studies suggest that association o f  n N O S  with 
the dystrophin complex is mediated by direct binding o f  
the NH2-terminus  o f  n N O S  to the P D Z  domain o f  c~l- 
syntrophin (29). However ,  during skeletal muscle develop-  
ment,  we found a dissociation between n N O S  and oel-syn- 
t rophin localization in muscle. Throughout  postnatal rat 
development ,  o t l -syntrophin was present at extrajunctional 
sarcolemma and was particularly enriched at neuromuscular  
endplates (Fig. 1). By contrast, at postnatal day 3 (P3) and 
P7, n N O S  was observed only at extrajunctional sarco- 
lemma. Enr ichment  o f  nNOS at neuromuscular  endplates 
did not  become apparent until P12, coincident  with accu- 
mulat ion o f  dystrophin at endplates. Ut rophin  was en-  
r iched at endplates in all stages evaluated. 
W e  compared n N O S  and ot l -syntrophin expression in 
Figure 1. Localization of nNOS and other dystrophin-associated proteins during postnatal development. Adjacent sections of postnatal rat quadriceps 
muscle were stained for dystrophin, nNOS, oe-BGT, and utrophin, and nearby sections were stained for otl-syntrophin and cx-BGT. Dystrophin and 
uNOS stained extrajunctional sarcolemma at P3 and P7 and both became concentrated at neuromuscular endplates at P12 and P60. otl-syntrophin was 
present at extrajunctional sarcolemma and was enriched at neuromuscular endplates at all ages evaluated. Utrophin staining was restricted to neuromuscu- 
lar endplates. 
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Figure 2. Localization of nNOS and ~xl-syntrophin in transgenic mdx mice. Cryosections from mouse quadriceps were double labeled for either 
nNOS or ~xl-syntrophin and cr Immunofluorescent staining showed that nNOS in wild-type mouse was expressed at extrajunctional sareolemma of 
a subset of fibers and was enriched at all neuromuscular endplates, nNOS was absent from junctional and extrajunctional sarcolemma in mdx mice. nNOS 
staining in mdx transgenic mice expressing full-length dystrophin (full-dys) or truncated dystrophin lacking the COOH-termina1330 nucleotides (A331)) 
resembled that of wild-type mice. mdx mice expressing dystrophin-lacking exons 17--48 (AEXON 17-48 mini-dys) or the COOH-terrmna171 kD of dystro- 
phin Dp7l lacked nNOS staining at sarcolemma, similar to nontransgenic mdx mouse, otl-syntrophin occurred at extrajunctional sarcolemma a~ad was 
concentrated at neuromuscular endplates in wild-type mice and was restricted to the endplates in mdx mouse, cd-syntrophin expression was restored to 
sarcolemma in the four transgenic mdx mouse lines expressing different portions of the dystrophin gene. 
skeletal muscle o f  wi ld- type ,  mdx, and  various transgenic 
mdx mice (Fig. 2) that express mu tan t  forms of  dystrophin 
(8, 9, 19-21,  35). As previously reported,  o t l - syn t roph in  
was absent f rom extrajunct ional  sarcolemma o f  mdx mouse ,  
bu t  remained  at neuromuscu la r  endplates (31, 36). n N O S  
was absent f rom bo th  junc t iona l  and extrajunct ional  sarco- 
lemma o f  mdx mouse.  Four  lines of  mdx transgenic mice 
were evaluated. These  previously described lines express ei- 
ther ful l - length dystrophin (line 8 6 2 C A A  [201), or various 
t runcated  dystrophins,  lacking either the 330 nucleot ides of  
exons 7 1 - 7 4  near  the C O O H - t e r m i n u s  (A330 [35]), lack- 
ing exons 17-48  of  the spectrinlike mo t i f  (AE17-48; 
C V B A  line 12142 [20]), or  lacking all bu t  the C O O H - t e r -  
minal  71 kD (Dp71; M C A - 1  [8, 9]). As previously re- 
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Figure 3. Subcellular distribution of  nNOS in transgenic mdx mouse. 
Mouse quadriceps skeletal muscle homogenates were sequentially ex- 
tracted with buffers containing 100 mM NaC1 (S1), 500 mM NaCI ($2), 
and 0.5% Triton X-100 ($3), leaving an insoluble cytoskeletal pellet (P). 
(A) Western blotting indicated that nNOS was enriched in membrane- 
associated and pellet fractions in wild-type mouse (lanes 1) and transgenic 
mdx mice expressing full-length dystrophin (lanes 4). In mdx mouse (lanes 
2) and Dp71 transgenic mdx mouse (lanes 3), nNOS was fully extracted 
by 500 mM NaCI and was absent from membrane-associated and cyto- 
skeletal fractions. (B and C) A similar fractionation was performed on 
muscle homogenates from wild-type nmuse (lanes 1), mdx mouse express- 
ing dystrophin-lacking exons 17-48 (lanes 2), or mdx mouse expressing 
fill-length dystrophin (lanes 3). (B) nNOS was absent from membrane- 
associated ($3) and cytoskeletal pellet (P) in mdx mouse expressing the 
truncated dystrophin. (C) R.eprobing the blot shows that od-syntrophin 
had a generally similar fractionation in nmscle from all three mice lines. 
p o r t e d ,  o L l - s y n t r o p h i n  e x p r e s s i o n  was  r e s t o r e d  to  j u n c -  
t iona l  a n d  e x t r a j u n c t i o n a l  s a r c o l e m m a  in  e a c h  o f  t h e  f o u r  
t r ansgen ics .  B y  con t ra s t ,  n N O S  was  r e s t o r e d  to  t h e  s a r c o -  
l e m m a  o n l y  b y  f u l l - l e n g t h  d y s t r o p h i n  a n d  t h e  A 3 3 0  m u -  
tant .  
Figure 4. Selective interaction o fnNOS and od-syntrophin. Crude sol- 
ubilized membranes from mouse quadriceps were titrated with NaOH to 
pH 11, to dissociate the dystrophin complex, and were neutralized to pH 7.4 
with 1 M Tris-HC1. Native and dissociated (&~soc) preparations were incu- 
bated with agarose beads linked to either GST or GST fused to the first 299 
anfino acids ofnNOS (G-NOS). After extensive washing, beads were eluted 
with loading buffer and proteins were resolved by SDS/PAGE. (A) West- 
em blotting showed that txl-syntrophin was selectively retained by G-NOS 
beads in both native and dissociated preparations. Reprobing the same 
blot with (B) dystrophin or (C) ot-sarcoglycan revealed that G-NOS beads 
retained these proteins from native protein preparations. However, after 
dissociation of  the complex, neither dystrophin nor ot-sarcoglycan bound 
to G-NOS. The 55-kD band observed in input lanes from r 
blot appears to be mouse IgG and was reactive with the secondary anti- 
body used for Western blotting. (D) Coimmunoprecipitation ofnNOS with 
otl-syntrophin from wild-type and mdx mouse skeletal muscle. Total sol- 
ubilized extract from mdx (lanes 1 and 2) or solubilized membranes from 
wild-type (lanes 3 and 4) mouse quadriceps were immunoprecipitated with 
an antibody to od-syntrophin (lanes 1 and 3) or nonimmune serum (lanes 
2 and 4). Western blotting indicates that nNOS was specifically coimmu- 
noprecipitated with oel-syntrophin from mdx and wild-type extracts. 
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Table  1. Sarcolemmal Expression of nNOS, Dystrophin, and Syntrophin in BMD 
Imunofluorescence at sarcolenlnla 
Exons deleted 
Diagnosis (mutation) Age at biopsy nNOS Dystrophin Syntrophin 
Normal 53 + + + + + + + + + + + + 
Normal 41 + + + + + + + + + + + + 
Mild BMD 45-47 30 0 + + + + + + + + 
Mild BMD 52 29 + + + + + + + + + + + 
Mild BMD 45-48 8 + + + + + + + + + 
Int. BMD 3-6 13 + + + +  + + + +  
Int. BMD 10-42 24 0 + + + + + + + + 
Int. BMD 13-41 12 + +  + + +  + + + +  
Int. BMD 45 23 0 + + + 
Sev. BMD 8 10 0 + + + + 
Sev. BMD 3-7 7 0 + + + + 
Sev. BMD 45-47 t0 0 + + +  + + + +  
Sev. BMD 51-52 9 (I + + + + 
a-sarcoglycanopathy (L31P/R284C) l l  + + + + + + + + + + + + 
{x-sarcoglycanopathy (P,77C/P,.77C) 8 + + + + + + + + + + 
Human muscle biopsies were labeled by immunofluorescence. Sarcolemmal labeling was blindly evaluated by three observers from {) to + + + +. 
Variation between observers never varied by more than one +, and for those cases, the majority score is reported, bit., intermediate; Sev., severe. 
Biochemical  studies confirmed that n N O S  did not  asso- 
ciate with sarcolemma in mdx mice or transgenic mdx mice 
expressing either Dp71 or  ~E17-48.  In wi ld- type and mdx 
transgenic mice expressing full-length dystrophin, n N O S  
was enriched in membrane-associated and cytoskeletal frac- 
tions, whereas in mdx, Dp71, and ZXE17-48 lines, n N O S  
was present only in soluble fractions of  muscle. As previ-  
ously reported, ed-synt rophin  occurred in sarcolemmal 
fractions of  all four lines o f  transgenic mdx mice evaluated 
(Fig. 3, and data not shown). 
Whereas these studies are consistent with the model  that 
association of  n N O S  with ed-synt rophin  in vivo requires a 
full-length dystrophin, direct binding o f n N O S  to the rodlike 
domain of  dystrophin or another dystrophin-associated 
protein could also explain the data. Previous studies dem-  
onstrate that the NH2-terminal domain o f n N O S  is necessary 
and sufficient for interaction with the dystrophin complex 
(28). W e  therefore evaluated interact ion o f  dys t rophin-  
associated proteins with a purified fusion protein contain- 
ing the first 299 amino acids o f n N O S .  As previously dem-  
onstrated, a Sepharose column linked to this fusion protein 
selectively retained several components  of  the dystrophin 
complex from crude skeletal muscle extracts. To determine 
which components  directly interact with n N O S  in vitro, 
we dissociated the dystrophin complex by briefly adjusting 
the pH of  muscle extracts to 11 and then repeating the 
binding assays immediately after neutralizing the extracts. 
Previous studies (37) have demonstrated that this procedure 
reversibly dissociates dystrophin from associated proteins. 
After dissociation o f  the complex, ed-synt rophin  contin-  
ued to interact with the n N O S  column but dystrophin, 
tx-sarcoglycan, and [3-dystroglycan were not retained (Fig. 
4, A - C  and data not  shown). 
To further verify that n N O S  directly interacts with syn- 
trophin in vivo, we conducted inmmnoprecipi ta t ion ex- 
periments in mdx mouse (Fig. 4/7)). A polyclonal antibody 
to ed-synt rophin  specifically coimnmnoprecipi ta ted a small 
amount  of  n N O S  from extracts of  mdx skeletal nmscle. 
n N O S  was more efficiently coinmmnoprecipi tated with e~ 1- 
syntrophin from solubilized membranes of  wild-type mouse 
as previously shown (29). 
W e  next asked whether  mutations in the NH2-terminal  
or rodlike domains of  dystrophin that cause B M D  in hu-  
mans were associated with altered localization of  nNOS.  
W e  immunohistochemical ly  evaluated n N O S  and txl-syn-  
trophin expression in 12 B M D  patients with molecularly 
defined deletions in the dystrophin gene. Immunohis-  
tochemical expression o f  nNOS,  dystrophin, and syntro- 
phin were assessed blindly. Loss ofsarcolemmal n N O S ,  but  
not cd-synt rophin  expression was associated with Becker 
phenotype (Table 1). Some o f  the patients, with mild to in- 
termediate disease, showed reduced but detectable n N O S  
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Figure 5. nNOS is absent from skeletal muscle sarcolemma in certain patients with BMD. Skeletal muscle cryosections from human biopsies were im- 
munostained with monoclonal antibodies to dystrophin, syntrophin, ot-sarcoglycan, or polyclonal antibody nNOS. All four antibodies showed sarcolem- 
mal staining in normal patients and essentially no sarcolemmal labeling in patients with DMD. In two patients with BMD, due to loss of exons 45-47 or 
10-42 of dystrophin, immunofluorescent labeling for dystrophin, syntrophin, and ot-sarcoglycan was detected at the membrane. By contrast, nNOS sar- 
colemmal staining was undetectable in these two BMD patients, nNOS labeling was present in a patient with ot-sarcoglycan deficiency. 
staining ofsarcolemma.  In several patients, loss ofsarco lem-  
mal n N O S  occurred despite apparently normal assembly o f  
other components  o f  the dystrophin-associated glycopro-  
tein complex (Fig. 5). By contrast, we found that n N O S  
expression was intact in two patients with primary et-sar- 
coglycan deficiency. This is consistent with the normal sta- 
tus o f  dystrophin and syntrophins in this disorder. 
Discuss ion  
A principal finding o f  this work  is that assembly o f  
n N O S  into the dystrophin complex is dependent  upon the 
normal structure o f  the rodlike domains ofdyst rophin .  Pre-  
vious analyses o f  specific protein contacts involved in main-  
tenance o f  the dystrophin complex have focused on protein 
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interactions at the N H  2- and C O O H - t e m n i n a l  domains o f  
dystrophin. These studies identify a functional F-actin 
binding site near  the N H a - t e r m i n u s  (7) and b ind ing  sites 
for 13-dystroglycan and syntrophins in the C O O H - t e r m i -  
nal domain o f  dystrophin (10). Understanding the mecha-  
nism for n N O S  association with the dystrophin complex is 
important  because n N O S  is uniquely absent from sarco- 
lemma in certain animal models o f  muscular dystrophy and 
in certain patients with BMD.  Absence o f  sarcolemmal 
n N O S  in mdx mouse expressing a dystrophin minigene in-  
dicates a role for the rodlike domain o f  dystrophin for 
binding o f  n N O S .  Studies o f  n N O S  expression in B M D  
patients demonstrate that distinct deletions in the NH2- te r -  
minal or central domain o f  dystrophin disrupt recrui tment  
o f  n N O S  to the sarcolemma. These results indicate that a 
unique nNOS interaction domain may not be present in 
dystrophin, but that proper conformation is required for as- 
sembly o fnNOS into the dystrophin complex. 
Previous studies suggest that direct interaction of nNOS 
with 0d-syntrophin accounts for association of nNOS with 
the dystrophin complex (29). Three syntrophin genes have 
been identified and each contains two pleckstrin homology 
(PH) domains. The first PH domain is split by a PDZ mo- 
tif, and the second PH domain is followed by a C O O H -  
terminal region unique to the syntrophins (38). Interaction 
of nNOS with ~xl-syntrophin is mediated by direct associa- 
tion of PDZ protein-binding interfaces near the NH2-ter- 
minus of nNOS and cxl-syntrophin. Studies here are con- 
sistent with this model and demonstrate that &l-syntrophin, 
but not dystrophin, [3-dystroglycan or cl-sarcoglycan binds 
to the PDZ-containing domain of nNOS. NOS isoforms 
lacking a PDZ motif do not associate with the dystrophin 
complex, further suggesting that the PDZ domain of 
nNOS represents the relevant domain for interaction (29). 
The precise binding site(s) for syntrophins within the 
dystrophin complex is uncertain. In vitro studies show that 
the COOH-terminal region of syntrophin directly interacts 
with a splice-prone COOH-terminal domain ofdystrophin 
(39-41). However, syntrophins are present in dystrophin 
complexes of the A330 transgenic mouse that lacks the 
identified syntrophin interaction domain, suggesting addi- 
tional bindings sites for syntrophins (35). It is not clear 
which domain of syntrophins might interact with these ad- 
ditional sarcolemmal binding sites. PH domains are known 
to interact with specific membrane proteins and phospho- 
lipids (42), and these regions of syntrophins represent can- 
didate interaction domains. Because the first PH domain of 
syntrophin is split by the PDZ domain (38), it is possible 
that sinmltaneous occupation of the PH1 and PDZ sites is 
sterically prohibited. Therefore, membrane association of 
syntrophin mediated by its PH domains could preclude 
binding of nNOS to the PDZ domain. This may explain 
the observed sarcolemmal expression of syntrophin and ab- 
sence o fnNOS in certain disease states. 
nNOS appears not to interact with utrophin-containing 
complexes. During early postnatal muscle development, 
nNOS is not concentrated with complexes of cxl-syntro- 
phin and utrophin at neuromuscular endplates. Similarly, 
utrophin complexes at neuronmscular endplates of mdx 
mouse lack nNOS. Taken together with biochemical stud- 
ies showing direct interaction of nNOS with Rl-syntro- 
phin in vitro, we propose that sarcolemmal localization of 
nNOS requires both syntrophin and dystrophin. It is alter- 
natively possible that nNOS primarily binds directly to dys- 
trophin in vivo. We have, however, been unable to detect 
direct interaction between nNOS and dystrophin in vitro 
and would disfavor this model. Future studies o fnNOS ex- 
pression in mice lacking syntrophin isoforms may be neces- 
sary to definitively clarify this issue. 
Loss of sarcolemmal nNOS does not appear to be a ge- 
neric consequence of muscle disease, nNOS expression oc- 
curs normally at the sarcolemma in a variety of inflamma- 
tory, neuropathic, and idiopathic muscle disorders (Chao, 
D.S., and D.S. Bredt, unpublished observations), and in dy 
mutant mice that have muscular dystrophy associated with 
loss of extracellular M-laminin (merosin; 28). Three pa- 
tients with similar deletions of exons 45-47 of dystrophin 
all showed loss of sarcolemmal nNOS but exhibited a wide 
spectrum of clinical variability. This domain of dystrophin 
is apparently critical for assembly ofnNOS,  and the clinical 
differences could be caused by environmental and/or epi- 
genetic factors, nNOS was expressed normally in two pa- 
tients with autosomal recessive muscular dystrophy due to 
mutations in oL-sarcoglycan (adhalin). Abnormality of nNOS 
expression, therefore, appears specific for dystrophin-related 
disease, and immunohistochernical analysis for nNOS may 
provide a supplemental diagnostic test. 
Abnormal expression of nNOS may play a role in the 
pathophysiology of BMD. Decreased expression of nNOS 
alone is not sufficient to produce muscular dystrophy, as we 
have not detected muscle pathology in nNOS a/a mice that 
have a targeted disruption o fn N O S  (Chao, D.S., and D.S. 
Bredt, unpublished observations). However, endogenous 
NO does play a role in regulation of skeletal muscle devel- 
opment and contractility (24, 26). Disruption of these NO 
signaling pathways may contribute to abnormal nmscle 
function and incomplete myofiber regeneration seen in 
muscular dystrophy. In mdx mice expressing Dp71 or dys- 
trophin minigene, nNOS is the only known dystrophin- 
associated protein absent from the sarcolemnaa. Transgenic 
mdx mice expressing the dystrophin minigene have an ex- 
tremely mild muscular dystrophy characterized by only a 
modest increase in central nuclei and serum pyruvate kinase 
activity (20, 21). A human patient with an identical muta- 
tion had a mild dystrophy and was ambulatory with the aid 
of a stick at age 61 (43). In contrast to the mild clinical 
phenotype, this minigene mutation in a 25-year-old patient 
was associated with severe histopathological nmscle fiber 
atrophy, extensive replacement by fat and fibrous connec- 
tive tissue, and few surviving fibers of normal diameter (43). 
These findings may be relevant in designing therapies for 
DMD. We find that nNOS does not associate with utro- 
phin-containing complexes, so that strategies for upregula- 
tion ofutrophin in DMD would not be expected to restore 
sarcolemmal nNOS. Because of the large size of the dystro- 
phin protein, vectors for gene therapy may need to encode 
truncation mutants. Expression ofa minigene lacking exons 
17-48 of dystrophin fails to recruit nNOS to sarcolemma 
of mdx mouse and is associated with a very mild Becket 
phenotype. Complete rescue of muscle function may re- 
quire replacement with dystrophin constructs that properly 
recruit nNOS to skeletal muscle membranes. 
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